Therapeutic targeting in the silent era: advances in non-viral siRNA delivery
Identifieur interne : 000D33 ( Main/Exploration ); précédent : 000D32; suivant : 000D34Therapeutic targeting in the silent era: advances in non-viral siRNA delivery
Auteurs : Jianfeng Guothese Author Made An Equal Contribution To This Work. [Irlande (pays)] ; Karen A. Fisher [Irlande (pays)] ; Raphael Darcy [Irlande (pays)] ; John F. Cryan [Irlande (pays)] ; Caitriona Odriscoll [Irlande (pays)]Source :
- Molecular BioSystems [ 1742-206X ] ; 2010.
English descriptors
- Teeft :
- Abcd, Antisense, Biol, Biosyst, Biotechnol, Cationic, Chem, Clinical trials, Cryan, Cyclodextrin, Cyclodextrins, Darcy, Delivery system, Drug delivery, Drug discovery, Endosomal, Gene, Gene delivery, Gene therapy, Huang, Immune, Immune response, Intracellular, Intravenous, Intravenous administration, Lipid, Lipoplexes, Liposome, Mammalian cells, Metastatic, Naked sirna, Nanoparticles, Natl, Nucleic, Nucleic acids, Ovarian, Pathway, Pegylation, Peptide, Pharm, Pharmaceutics, Polycations, Polymer, Polyplexes, Receptor, Rna, Rnai, Rnai pathway, Royal society, Sato, Sirna, Sirna delivery, Sirnas, Systemic delivery, Therapeutics, Transfected, Transfection, Transferrin, Tumour, University college cork, Vegf, Vesicle, Viral, Vivo, Wang, Zhang.
Abstract
Gene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated.
Url:
DOI: 10.1039/c001050m
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000910
- to stream Istex, to step Curation: 000889
- to stream Istex, to step Checkpoint: 000100
- to stream Main, to step Merge: 000D35
- to stream Main, to step Curation: 000D33
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Therapeutic targeting in the silent era: advances in non-viral siRNA delivery</title><author wicri:is="90%"><name sortKey="Guothese Author Made An Equal Contribution To This Work, Jianfeng" sort="Guothese Author Made An Equal Contribution To This Work, Jianfeng" uniqKey="Guothese Author Made An Equal Contribution To This Work J" first="Jianfeng" last="Guothese Author Made An Equal Contribution To This Work.">Jianfeng Guothese Author Made An Equal Contribution To This Work.</name></author><author wicri:is="90%"><name sortKey="Fisher, Karen A" sort="Fisher, Karen A" uniqKey="Fisher K" first="Karen A." last="Fisher">Karen A. Fisher</name></author><author wicri:is="90%"><name sortKey="Darcy, Raphael" sort="Darcy, Raphael" uniqKey="Darcy R" first="Raphael" last="Darcy">Raphael Darcy</name></author><author wicri:is="90%"><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name></author><author wicri:is="90%"><name sortKey="Odriscoll, Caitriona" sort="Odriscoll, Caitriona" uniqKey="Odriscoll C" first="Caitriona" last="Odriscoll">Caitriona Odriscoll</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A34210B0A4998AE897B553258296339DFCDCF6A</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1039/c001050m</idno><idno type="url">https://api.istex.fr/ark:/67375/QHD-NJTVVF3B-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000910</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000910</idno><idno type="wicri:Area/Istex/Curation">000889</idno><idno type="wicri:Area/Istex/Checkpoint">000100</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000100</idno><idno type="wicri:doubleKey">1742-206X:2010:Guothese Author Made An Equal Contribution To This Work J:therapeutic:targeting:in</idno><idno type="wicri:Area/Main/Merge">000D35</idno><idno type="wicri:Area/Main/Curation">000D33</idno><idno type="wicri:Area/Main/Exploration">000D33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Therapeutic targeting in the silent era: advances in non-viral siRNA delivery</title><author wicri:is="90%"><name sortKey="Guothese Author Made An Equal Contribution To This Work, Jianfeng" sort="Guothese Author Made An Equal Contribution To This Work, Jianfeng" uniqKey="Guothese Author Made An Equal Contribution To This Work J" first="Jianfeng" last="Guothese Author Made An Equal Contribution To This Work.">Jianfeng Guothese Author Made An Equal Contribution To This Work.</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>School of Pharmacy, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Irlande (pays)</country></affiliation></author><author wicri:is="90%"><name sortKey="Fisher, Karen A" sort="Fisher, Karen A" uniqKey="Fisher K" first="Karen A." last="Fisher">Karen A. Fisher</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>School of Pharmacy, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Irlande (pays)</country></affiliation></author><author wicri:is="90%"><name sortKey="Darcy, Raphael" sort="Darcy, Raphael" uniqKey="Darcy R" first="Raphael" last="Darcy">Raphael Darcy</name><affiliation wicri:level="4"><orgName type="university">University College Dublin</orgName><country>Irlande (pays)</country><placeName><settlement type="city">Dublin</settlement><region type="région" nuts="2">Leinster</region></placeName></affiliation></author><author wicri:is="90%"><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>School of Pharmacy, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Dept Pharmacology & Therapeutics, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Alimentary Pharmabiotic Centre, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Irlande (pays)</country></affiliation></author><author wicri:is="90%"><name sortKey="Odriscoll, Caitriona" sort="Odriscoll, Caitriona" uniqKey="Odriscoll C" first="Caitriona" last="Odriscoll">Caitriona Odriscoll</name><affiliation wicri:level="1"><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>School of Pharmacy, University College Cork, Cork</wicri:regionArea><wicri:noRegion>Cork</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Irlande (pays)</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Molecular BioSystems</title><title level="j" type="abbrev">Mol. BioSyst.</title><idno type="ISSN">1742-206X</idno><idno type="eISSN">1742-2051</idno><imprint><publisher>The Royal Society of Chemistry.</publisher><date type="published" when="2010">2010</date><biblScope unit="volume">6</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1143">1143</biblScope><biblScope unit="page" to="1161">1161</biblScope></imprint><idno type="ISSN">1742-206X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1742-206X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abcd</term><term>Antisense</term><term>Biol</term><term>Biosyst</term><term>Biotechnol</term><term>Cationic</term><term>Chem</term><term>Clinical trials</term><term>Cryan</term><term>Cyclodextrin</term><term>Cyclodextrins</term><term>Darcy</term><term>Delivery system</term><term>Drug delivery</term><term>Drug discovery</term><term>Endosomal</term><term>Gene</term><term>Gene delivery</term><term>Gene therapy</term><term>Huang</term><term>Immune</term><term>Immune response</term><term>Intracellular</term><term>Intravenous</term><term>Intravenous administration</term><term>Lipid</term><term>Lipoplexes</term><term>Liposome</term><term>Mammalian cells</term><term>Metastatic</term><term>Naked sirna</term><term>Nanoparticles</term><term>Natl</term><term>Nucleic</term><term>Nucleic acids</term><term>Ovarian</term><term>Pathway</term><term>Pegylation</term><term>Peptide</term><term>Pharm</term><term>Pharmaceutics</term><term>Polycations</term><term>Polymer</term><term>Polyplexes</term><term>Receptor</term><term>Rna</term><term>Rnai</term><term>Rnai pathway</term><term>Royal society</term><term>Sato</term><term>Sirna</term><term>Sirna delivery</term><term>Sirnas</term><term>Systemic delivery</term><term>Therapeutics</term><term>Transfected</term><term>Transfection</term><term>Transferrin</term><term>Tumour</term><term>University college cork</term><term>Vegf</term><term>Vesicle</term><term>Viral</term><term>Vivo</term><term>Wang</term><term>Zhang</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Gene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant pace. However, the widespread use of such approaches is contingent on having appropriate systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many physicochemical and biological barriers to such delivery, and a growing emphasis on the design and characterisation of non-viral technologies that will overcome these barriers and expedite targeted delivery. This review discusses the considerations and challenges associated with use of siRNA-based therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of the criteria of an ideal delivery construct is also elaborated.</div></front></TEI><affiliations><list><country><li>Irlande (pays)</li></country><region><li>Leinster</li></region><settlement><li>Dublin</li></settlement><orgName><li>University College Dublin</li></orgName></list><tree><country name="Irlande (pays)"><noRegion><name sortKey="Guothese Author Made An Equal Contribution To This Work, Jianfeng" sort="Guothese Author Made An Equal Contribution To This Work, Jianfeng" uniqKey="Guothese Author Made An Equal Contribution To This Work J" first="Jianfeng" last="Guothese Author Made An Equal Contribution To This Work.">Jianfeng Guothese Author Made An Equal Contribution To This Work.</name></noRegion><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name><name sortKey="Cryan, John F" sort="Cryan, John F" uniqKey="Cryan J" first="John F." last="Cryan">John F. Cryan</name><name sortKey="Darcy, Raphael" sort="Darcy, Raphael" uniqKey="Darcy R" first="Raphael" last="Darcy">Raphael Darcy</name><name sortKey="Fisher, Karen A" sort="Fisher, Karen A" uniqKey="Fisher K" first="Karen A." last="Fisher">Karen A. Fisher</name><name sortKey="Fisher, Karen A" sort="Fisher, Karen A" uniqKey="Fisher K" first="Karen A." last="Fisher">Karen A. Fisher</name><name sortKey="Guothese Author Made An Equal Contribution To This Work, Jianfeng" sort="Guothese Author Made An Equal Contribution To This Work, Jianfeng" uniqKey="Guothese Author Made An Equal Contribution To This Work J" first="Jianfeng" last="Guothese Author Made An Equal Contribution To This Work.">Jianfeng Guothese Author Made An Equal Contribution To This Work.</name><name sortKey="Odriscoll, Caitriona" sort="Odriscoll, Caitriona" uniqKey="Odriscoll C" first="Caitriona" last="Odriscoll">Caitriona Odriscoll</name><name sortKey="Odriscoll, Caitriona" sort="Odriscoll, Caitriona" uniqKey="Odriscoll C" first="Caitriona" last="Odriscoll">Caitriona Odriscoll</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8A34210B0A4998AE897B553258296339DFCDCF6A
|texte= Therapeutic targeting in the silent era: advances in non-viral siRNA delivery
}}
| This area was generated with Dilib version V0.6.33. |  |